# A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours

> **NCT02977364** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Carcinoma
- Solid Tumor, Adult

## Interventions

- **DRUG:** HS-10241

## Key facts

- **NCT ID:** NCT02977364
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2018-11
- **Final completion:** 2021-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02977364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02977364, "A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02977364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*